By continuing to use our service, you agree to our use of cookies. MONTREAL, Nov. (THTX) Stock Price, Quote & News - Stock Analysis -20. See a list of the most recent Stock Forum posts on Stockhouse. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. We also use them to share usage. ( THTX 3. 75. Stockhouse. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. 17% from a day low at $1. Company Description: Theratechnologies is pepped up on peptides. 72%. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. 24 million, 48. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. - Issued and outstanding common shares to be consolidated on the basis of 1 post. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. TO) on CEO. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 25. MONTREAL, Aug. Non-Profit & Charitable Organizations · United States · <25 Employees. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 67% from the latest price. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. “This is yet another major achievement for our oncology program. By continuing to use our service, you agree to our use of cookies. We also use them to share. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. 49%) At close: 04:00PM EST 1. 8 and 1. TH | Complete Theratechnologies Inc. 8. TH | September 26, 2023. 5% workforce reduction. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Stockhouse. Paul Levesque - President. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. We also use them to. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - October 10, 2023) - KO Gold Inc. By continuing to use our service, you agree to our use of cookies. 22M. 2 million. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Theratechnologies Inc. T. T. By continuing to use our service, you agree to our use of cookies. MONTREAL, Jan. The company reported ($0. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. $30. 54% and a negative trailing twelve-month return on equity of. Proceeds to Be Used to Redeem All of the Outstanding 5. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. 00 to $36. Cookies are used to offer you a better browsing experience and to analyze our traffic. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Q3 2023 consolidated revenue of $20. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Stockhouse. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. com uses cookies on this site. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. Find more information. 69 to $1. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. com uses cookies on this site. 06 million, an increase of. By continuing to use our service, you agree to our use of cookies. Stockhouse. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies Inc. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. 81 million for the quarter. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. 69, 1. Biopharmaceutical company Theratechnologies Inc. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. (THTX) stock. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Theratechnologies Stock Price, News and Company Updates. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. By continuing to use our service, you agree to our use of cookies. Q4 2022 consolidated revenue growth of 14. Cookies are used to offer you a better browsing experience and to. It is the Company’s proprietary. com uses cookies on this site. S. By continuing to use our service, you agree to our use of cookies. (2013-04-03 | TSX:TH) Theratechnologies Inc. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. Their average twelve-month price target is $36. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. By continuing to use our service, you agree to our use of cookies. MONTREAL, Feb. Theratechnologies had a negative net margin of 36. The company reported ($0. H. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Focused on small-cap companies and sectors. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. TH | February 28, 2023. THTX earnings call for the period ending February 29, 2020. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Losses were -47. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Elif McDonald - Senior Director, Investor Relations. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. Cookies are used to offer you a better browsing experience and to analyze our traffic. A high-level overview of Theratechnologies Inc. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. -4. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. Saint-Laurent, Canada. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. com uses cookies on this site. com uses cookies on this site. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 33 +0. Further. . Cookies are used to offer you a better browsing experience and to analyze our traffic. This news release constitutes a “designated news release” for the purposes. 617-356-1009. 4% annually. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. By continuing to use our service, you agree to our use of cookies. This module allows you to check different measures of market premium (i. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . Cookies are used to offer you a better browsing experience and to analyze our traffic. 71. We currently market prescription products for people with HIV in the United States. We also use them to share usage. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. - Cash, bonds and money market funds of US$22. The Company currently commercializes two products in the field of HIV. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. By continuing to use our service, you agree to our use of cookies. TH | July 20, 2023. Volume has increased on the last day along with the price, which is a. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. We also use them to share usage. 's motion for leave to commence. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Stockhouse. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. We also use them to share usage. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. - Q3 2022 Consolidated Revenue Growth of 17% to $20. Remember, high Theratechnologies' alpha is almost always a sign of. 4%. Following the release, Knight will hold a conference call and audio webcast. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. 2% per year. 4 million. According to 3 analysts, the average rating for THTX stock is "Buy. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. Marsolais’ presentation will be available through. Theratechnologies Inc. T. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. com uses cookies on this site. " The 12-month stock price forecast is $18. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. Montréal, Québec, Canada . By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 68 to a day high of $1. 39 50-Day Range $0. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. European Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 1-438. Their THTX share price targets range from $36. . MONTREAL, Sept. October 13, 2022 07:30 ET | Source: Theratechnologies. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. MONTREAL, Feb. 4. 51 S1. 26 +15. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. (TH. 60%. Theratechnologies's earnings have been declining at an average annual rate of -35. View real-time stock prices and stock quotes for a full financial overview. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. - On track to meet FY2022. By continuing to use our service, you agree to our use of cookies. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The reported ($0. 9 million, adjusted EBITDA of $2. Theratechnologies Appoints New Board Member. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. Share your ideas and get valuable. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Follow. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. 35 as of 10:41 a. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. $103. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. Cookies are used to offer you a better browsing experience and to. 49) by $0. The abstracts are now available at aacr. When this page refreshes you will be logged in with the new address. Find the latest Theratechnologies Inc. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Headquarters. 5000 +0. , alpha and beta) for all equities such as Theratechnologies. Stockhouse. Theratechnologies Inc. Theratechnologies Inc. com uses cookies on this site. 5000 0. Story. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. com uses cookies on this site. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. 89 52. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. 40%. 4%. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. THERATECHNOLOGIES INC. This news release constitutes a. TH | September 5, 2023. W. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. . By continuing to use our service, you agree to our use of cookies. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. Biopharmaceutical company Theratechnologies Inc. 05M. Stockhouse. . com. TH | September 5, 2023. [email protected] Inc: Overview. Stockhouse. TH | February 28, 2023. By continuing to use our service, you agree to our use of cookies. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. (TH. 57%) Q1 2020 Earnings Call. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. - 2023 Q3 positive adjusted EBITDA to be. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Stockhouse. The Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Stockhouse. ir@theratech. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Find the latest Theratechnologies Inc. About TH1902. Theratechnologies Inc. Theratechnologies . However, only about 4% of the stocks on the OTC market fall into this category. About SORT1+ Technology™ and TH1902. MONTREAL, Oct. Stockhouse. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. e. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Aug. 40 f102M H1. (882) posted 3 minutes ago. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (2013-04-03 | TSX:TH) Theratechnologies Inc. Stockhouse. MONTREAL, Oct. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. Northwest also announces an update on its.